Cholesterol Management - Understanding the 2018 Guideline
Cardiovascular disease (CVD), which includes high blood pressure, stroke, heart failure, and coronary heart disease, is prevalent and costly. Coronary heart disease is the most common form, accounting for 43% of all deaths attributed to CVD. The underlying pathophysiology of CVD is atherosclerosis; hence the term atherosclerotic cardiovascular disease (ASCVD). Risk factor management and treatment are essential to prevent CVD progression, cardiovascular events, and costly healthcare... Read More »
The popularity of medical marijuana (also known as medical
cannabis) continues to grow in the US. In 2018, over 3.5 million
patients were registered to use medical cannabis; an increase
from 2.6 million in March, 2016. As of January 2019, 33 states
and Washington D.C., have laws legalizing medical marijuana.
Ten states, Washington D.C., and Canada have legalized recreational
marijuana. In addition, a growing number of states
have laws specifically addressing the use of cannabidiol (CBD)
for medical, as well as nonmedical, purposes.
The use of Cannabis sativa by the Chinese – for its strength as
a fiber (in paper, bowstrings, rope, or clothing) and its medicinal
properties... Read More »
New Drugs 2018
In 2018, the US Food and Drug Administration (FDA) approved 59 new drugs – the highest number in more than 10 years – including 19 first-in-class agents.
Of the 59 new approvals, 73% received priority review. This issue of The Rx Consultant focuses on the new drugs that may be important additions (including a number of “firsts”) in their therapeutic areas: influenza infection, HIV-1 infection, pneumonia and skin infections, nonmetastatic, castration-resistant prostate cancer, endometriosis, migraine prophylaxis, moderate to severe acne, and chronic, idiopathic constipation.
Dosing and drug interactions are detailed in Table 1. Brief descriptions of selected additional new drugs... Read More »